The use of minimized extracorporeal circulation system has a beneficial effect on hemostasis - A randomized clinical study

Heart Surgery Forum

Volumn 9, Issue 1, 2006, Pages 39-44

  Abdel Rahman, Ulf ^a   Martens, Sven ^a   Risteski, Petar ^a   Özaslan, Feyzan ^a   Riaz, Musawir ^a   Moritz, Anton ^a   Wimmer Greinecker, Gerhard ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPLASMIN; ANTITHROMBIN III; D DIMER; FIBRINOGEN; FRESH FROZEN PLASMA; PLASMIN; PROTHROMBIN; THROMBOPLASTIN;

ADULT; AGED; AORTA CLAMPING; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; EXTRACORPOREAL CIRCULATION; FEMALE; HEMATOCRIT; HEMOSTASIS; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; BLOOD CLOTTING; COMPARATIVE STUDY; CORONARY ARTERY ATHEROSCLEROSIS; FIBRINOLYSIS; INSTRUMENTATION; MIDDLE AGED;

AGED; BLOOD COAGULATION; CARDIOPULMONARY BYPASS; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 33845326463     PISSN: 10983511     EISSN: None     Source Type: Journal    
DOI: 10.1532/HSF98.20051110     Document Type: Article

References (32)

1. Abdel-Rahman U, Ozaslan F, Risteski PS, et al. 2005. Initial experience with a minimized extracorporeal bypass system: is there a clinical benefit? Ann Thorac Surg 80:238-43.
2. Centers for Disease Control and Prevention. 2003. Life expectancy at birth, at 65 years of age, and at 75 years of age, according to race and sex: United States, selected years 1900-2001. Table 27. (Accessed December 16, 2004, at http://www.cdc.gov/nchs/data/hus/tables/2003/ 03hus027. pdf).
3. Chai PJ, Nassar R, Oakeley AE, et al. 2000. Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage. Circulation 101:541-6.
4. Daniel S. 1996. Review on the multifactorial aspects of bioincompatibility in CPB. Perfusion 11:246-55.
5. Edmunds, LH. 2004. Cardiopulmonary bypass after 50 years. N Engl J Med 351;16:1603-6.
6. Fallen D, Komorowski B, Groh M. 2003. Perfusion-assisted beating heart CABG with a miniature bypass system is associated with improved outcomes compared to traditional CPB-supported CABG. Heart Surg Forum 6:207-8.
7. Folliguet TA, Villa E, Vandeneyden F, Laborde F. 2003. Coronary artery bypass graft with minimal extracorporeal circulation. Heart Surg Forum 6:297-301.
8. Fromes Y, Gaillard D, Ponzio O, et al. 2002. Reduction of the inflammatory response following coronary bypass grafting with total minimal extracorporeal circulation. Eur J Cardiothorac Surg 22:527-33.
9. Gibbon JH Jr. 1954. Application of a mechanical heart and lung apparatus to cardiac surgery. Minn Med 37:171-85.
10. Gourlay T. 2001. Biomaterial development for cardiopulmonary bypass. Perfusion 16:381-90.
11. Gu Y, van Oeveren W, Akkerman C, Boonstra P, Huyzen R, Wildevuur C. 1993. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 55:917-22.
12. Hill GE, Alonso A, Thiele GM, Robbins RA. 1994. Glucocorticoids blunt neutrophil CD11b surface glycoprotein upregulation during cardiopulmonary bypass in humans. Anesth Analg 79:23-7.
13. Hill GE, Alonso A, Spurzem JR, et al. 1995. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 110:1658-62.
14. Jansen NJ, van Oeveren W, Gu YJ, van Vliet MH, Eijsman L, Wildevuur CR. 1992. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg 54:744-8.
15. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. 1983. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 86:845-57.
16. Luciani GB, Menon T, Vecchi B, et al. 2003. Modified ultrafiltration reduces morbidity after adult cardiac operations: a prospective, randomized clinical trial. Circulation 104(Suppl I):253-9.
17. Matheis G. 2001. Leukocyte filtration in cardiac surgery: a review. Perfusion 16:361-70.
18. Mon SS, Giroir BP, Molitor-Kirsch EA, et al. 2004. Fresh whole blood versus reconstituted blood for pump priming in heart surgery in infants. N Engl J Med 351:1635-44.
19. Muehrcke DD, McCarthy PM, Kottke-Marchant K, et al. 1996. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized masked clinical trial. J Thorac Cardiovasc Surg 112:472-83.
20. Mueller XM, Jegger D, Augstburger M, Horisberger J, Godar G, von Segesser LK. 2002. A new concept of integrated cardiopulmonary bypass circuit. Eur J Cardiothorac Surg 21:840-6.
21. Murase M, Usui A, Tomita Y, et al. 1993. Nafamostat mesilate reduces blood loss during open heart surgery. Circulation 88(Suppl II):432-6.
22. Naik SK, Knight A, Elliot M. 1991. A prospective randomized study of a modified technique of ultrafiltration during pediatric open-heart surgery. Circulation 84(Suppl III):422-31.
23. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. 1999. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 16:9-13.
24. Prondzinsky R, Knüpfer A, Lappnow H, et al. 2005. Surgical trauma affects the proinflammatory status after cardiac surgery to a higher degree than cardiopulmonary bypass. J Thorac Cardiovasc Surg 129:760-6.
25. Remadi JP, Marticho P, Butoi I, et al. 2004. Clinical experience with the mini-extracorporeal circulation system: an evolution or a revolution? Ann Thorac Surg 77:2172-6.
26. Scholz M, Simon A, Matheis G, et al. 2002. Leukocyte filtration fails to limit functional neutrophil activity during cardiac surgery. Inflamm Res 51:363-8.
27. Vaislic C, Bical O, Farge C, et al. 2003. Totally minimized extracorporeal circulation: an important benefit for coronary artery bypass grafting in Jehovah's witnesses. Heart Surg Forum 6:307-10.
28. von Segesser LK, Tozzi P, Mallbiabrrena I, Jegger D, Horisberger J, Corno A. 2003. Miniaturization in cardiopulmonary bypass. Perfusion 18:219-224.
29. Wachtfogel YT, Kucich U, Hack CE, et al. 1993. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 106:1-9.
30. Westaby S. Organ dysfunction after cardiopulmonary bypass. 1987. A systemic inflammatory reaction initiated by the extracorporeal circuit. Intensive Care Med 13:89-95.
31. Wimmer-Greinecker G, Matheis G, Martens S, Oremek G, Abdel-Rahman U, Moritz A. 1999. Synthetic protein treated versus heparin coated cardiopulmonary bypass surfaces: similar results and minor biochemical differences. Eur J Cardio-thorac Surg 16:211-17.
32. Zahler S, Massoudy P, Hartl H, Hahnel C, Meisner H, Becker BF. 1999. Acute cardiac inflammatory responses to postischemic reperfusion during cardiopulmonary bypass. Cardiovasc Res 41:722-30.